Compare Vaxcyte Inc. Common Stock (PCVX) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Venture Global Inc. Class A common stock trades at $13.23 (market cap $34.60B). The key difference: Venture Global Inc. Class A common stock is far larger — about 3.3× Vaxcyte Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| PCVX | VG | |
|---|---|---|
Market Cap | $10.51B | $34.60B |
Volume | 2,644,694 | 11,731,839 |
Sector | Health | Energy |
52-Week High | $73.82 | $17.53 |
52-Week Low | $40.32 | $5.92 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $9.14B | $73.99B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
